ArticleJournal of clinical medicine2022
Medium and Long-Term Outcome of Superselective Transcatheter Arterial Embolization with Lipiodol-Bleomycin Emulsion for Giant Hepatic Hemangiomas: Results in 241 Patients.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Transarterial embolization with bleomycin-lipiodol for symptomatic multifocal hepatic hemangiomas: Concurrent nontarget lesion devascularization via permitted reflux.Radiology case reports · 2026Article
- Management and Clinical Outcomes of Liver Hemangiomas: A Retrospective Comparative Study of Transcatheter Arterial Embolization and Surgery.Medicina (Kaunas, Lithuania) · 2026Article
- "No Touch to Touch": Percutaneous Sclerotherapy of a Giant Hepatic Cavernous Hemangioma.Cureus · 2026Article
- Clinical outcomes of combined transarterial chemoembolization and microwave ablation for hepatic hemangiomas: a comparative analysis of large versus. giant tumors.BMC gastroenterology · 2025Article
- Resistant Hilar Stricture Following Transarterial Bleomycin-Lipiodol Embolization for a Large Hepatic Hemangioma.ACG case reports journal · 2025Article
- Endovascular treatment of giant hepatic hemangiomas: a systematic review and meta-analysis.Jornal vascular brasileiro · 2025Review
- Case Report: Subcapsular hematoma post-transarterial embolization and its laparoscopic resolution.Frontiers in medicine · 2025Article
- Transarterial chemoembolization with bleomycin and lipiodol: a novel treatment for giant hepatic haemangiomas.Polish journal of radiology · 2025Article
- Article
- Reconsideration of the clinical management of hepatic hemangioma.World journal of gastrointestinal surgery · 2024Article
- Long-Term Outcomes of Transarterial Chemoembolization of Giant Liver Hemangiomas with Lipiodol-Bleomycin Emulsion.Cardiovascular and interventional radiology · 2024Article
- Article
- Transarterial embolization with bleomycin-lipiodol emulsion: a successful minimal invasive approach for giant liver hemangioma.Clinical journal of gastroenterology · 2024Article
- Hepatic Hemangioma: Review of Imaging and Therapeutic Strategies.Medicina (Kaunas, Lithuania) · 2024Review
- Article
- Postnatal treatment and evolution patterns of giant fetal hepatic hemangioma: a case series of 29 patients.BMC pediatrics · 2024Article
- Safety and Feasibility of Transarterial Bleomycin-Lipiodol Embolization in Patients with Giant Hepatic Hemangiomas.Medicina (Kaunas, Lithuania) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the medium and long-term efficacy of superselective transcatheter arterial embolization (TAE) with lipiodol−bleomycin emulsions (LBE) for giant hepatic hemangiomas. Methods: A total of 241 patients who had underwent TAE with LBE for hepatic hemangiomas from January 2010 to December 2016 were retrospectively reviewed. Blood tests were performed 3 and 7 days after TAE and procedural-related complications were recorded. The patients were followed up by enhanced CT or MRI imaging at 6, 12, 36, and 60 months post-TAE, respectively. Technical success of TAE was defined as successful embolization of all identifiable arteries supplying to the hemangiomas. Clinical success was defined as improvement of the abdominal symptoms and indications on the imaging examinations that the hemangiomas had decreased by more than 50% in maximum diameter. Results: TAE was performed successfully in all patients without serious complications. Improvement of the abdominal symptoms was recorded in 102/102 cases (100%). The reduction rate of the tumor maximum diameter with >50% at 6, 12, 36, and 60 months was 88.1% (190/210), 86.7% (170/196), 85.2% (124/142), and 86.5% (45/52), respectively. There was a significant change from pre-TAE to follow-up values in maximum diameter (p < 0.05). Conclusion: TAE with LBE was feasible and effective for giant hepatic hemangiomas. The reductions of the tumor maximum diameter with >50% at medium (≥3 years) and long-term (≥5 years) follow-up were satisfactory, with 85.2% and 86.5%, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.